Hypoaesthesia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:52:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hypoaesthesia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Ozone Treatment for Numbness and Tingling from Chemotherapy in Patients with Peripheral Neuropathy: A Clinical Trial https://clinicaltrials.eu/trial/ozone-treatment-for-numbness-and-tingling-from-chemotherapy-in-patients-with-peripheral-neuropathy-a-clinical-trial/ Wed, 29 Apr 2026 14:57:32 +0000 https://clinicaltrials.eu/trial/ozone-treatment-for-numbness-and-tingling-from-chemotherapy-in-patients-with-peripheral-neuropathy-a-clinical-trial/ This clinical trial is focused on studying the effects of a treatment for paresthesia, which is a condition characterized by numbness and tingling. This condition can occur as a side effect of chemotherapy, known as chemotherapy-induced peripheral neuropathy. The trial will explore the use of a treatment involving ozone, a form of oxygen, to see if it can help reduce these symptoms and improve the quality of life for patients experiencing moderate to severe paresthesia.

The treatment involves using a mixture of ozone and oxygen, which is administered through a method called rectal insufflation. This means the gas mixture is introduced into the body through the rectum. The study aims to determine if adding ozone to the usual care for paresthesia can help patients feel better and improve their daily lives. The trial will also look at how this treatment affects patients’ overall health and well-being over a period of time.

Participants in the study will receive the treatment over a period of 16 weeks, with follow-up assessments continuing for up to 28 weeks. The study will measure changes in the level of numbness and tingling that patients feel, as well as their overall quality of life. The goal is to find out if this new approach can offer a beneficial addition to the current management of paresthesia caused by chemotherapy.

]]>